{"id":"NCT01710657","sponsor":"UCB Pharma SA","briefTitle":"A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures","officialTitle":"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Uncontrolled Partial-Onset Seizures With or Without Secondary Generalization","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09","primaryCompletion":"2014-07","completion":"2014-08","firstPosted":"2012-10-19","resultsPosted":"2015-02-09","lastUpdate":"2017-08-25"},"enrollment":548,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy","Partial Onset Seizures"],"interventions":[{"type":"DRUG","name":"Lacosamide 50 mg","otherNames":["Vimpat"]},{"type":"DRUG","name":"Lacosamide 100 mg","otherNames":["Vimpat"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Lacosamide 200 mg/day","type":"EXPERIMENTAL"},{"label":"Lacosamide 400 mg/day","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of 200 and 400 mg/day of orally administered Lacosamide as adjunctive therapy compared with placebo in Japanese and Chinese adults with uncontrolled Partial-Onset Seizures with or without secondary generalization.","primaryOutcome":{"measure":"Change in Partial-Onset Seizure Frequency Per 28 Days From Baseline to the Maintenance Period","timeFrame":"8-week Baseline Period (Visit 1 to 3) and 12-week Maintenance Period (Visit 5 to 8)","effectByArm":[{"arm":"Placebo","deltaMin":-1.22,"sd":null},{"arm":"Lacosamide 200 mg/Day","deltaMin":-3.33,"sd":null},{"arm":"Lacosamide 400 mg/Day","deltaMin":-4.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":76,"countries":["China","Japan"]},"refs":{"pmids":["23859801"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":184},"commonTop":["Dizziness","Nasopharyngitis","Upper respiratory tract infection","Somnolence","Headache"]}}